Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9580456
SERIAL NO

14438977

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHOLD COLLEGE SOUTH BRIDGE EDINBURGH EH8 9YL

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Henderson, Neil Edinburgh, GB 9 20
Leffler, Hakon Lund, SE 27 152
MacKinnon, Alison Edinburgh, GB 6 21
Nilsson, Ulf Lund, SE 114 736
Sethi, Tariq Haddington, GB 6 21

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 28, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00